Midatech Pharma PLC (MTP): Price and Financial Metrics


Midatech Pharma PLC (MTP): $1.40

-0.06 (-4.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MTP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 502

in industry

MTP POWR Grades


  • MTP scores best on the Growth dimension, with a Growth rank ahead of 88.12% of US stocks.
  • MTP's strongest trending metric is Growth; it's been moving up over the last 173 days.
  • MTP ranks lowest in Value; there it ranks in the 6th percentile.

MTP Stock Summary

  • With a market capitalization of $18,165,269, Midatech Pharma Plc has a greater market value than only 1.1% of US stocks.
  • With a year-over-year growth in debt of -86.6%, Midatech Pharma Plc's debt growth rate surpasses just 3.08% of about US stocks.
  • Revenue growth over the past 12 months for Midatech Pharma Plc comes in at -94.49%, a number that bests only 1% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Midatech Pharma Plc are MESO, FF, HOLI, AEHL, and HMG.
  • Visit MTP's SEC page to see the company's official filings. To visit the company's web site, go to www.midatechpharma.com.

MTP Stock Price Chart Interactive Chart >

Price chart for MTP

MTP Price/Volume Stats

Current price $1.40 52-week high $3.83
Prev. close $1.46 52-week low $1.36
Day low $1.36 Volume 85,600
Day high $1.48 Avg. volume 900,513
50-day MA $1.68 Dividend yield N/A
200-day MA $1.95 Market Cap 17.75M

Midatech Pharma PLC (MTP) Company Bio


Midatech Pharma PLC focuses on the development and commercialization of multiple, high-value, targeted therapies for major diseases with high unmet medical need in the nanomedicine field.


MTP Latest News Stream


Event/Time News Detail
Loading, please wait...

MTP Latest Social Stream


Loading social stream, please wait...

View Full MTP Social Stream

Latest MTP News From Around the Web

Below are the latest news stories about Midatech Pharma Plc that investors may wish to consider to help them evaluate MTP as an investment opportunity.

Midatech Pharma moves to new waterside headquarters in Cardiff

Drug delivery technology company Midatech Pharma plc has moved its Cardiff headquarters to offices in Cardiff Bay. The company has moved to the 1 Caspian Point office building in Caspian Way, Pierhead Street part of the Parmer Cardiff campus on the citys waterfront, where it has created 8,050 sq ft of offices and laboratories on [] The post Midatech Pharma moves to new waterside headquarters in Cardiff appeared first on .

Wales 247 | September 21, 2021

Midatech Pharma formally opens its new Cardiff headquarters

Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced the formal opening today of its new headquarters, incorporating purpose built laboratory facilities and offices at 1 Caspian Point in Cardiff, UK. The Company has moved to the 1 Caspian Point building, part of the []

Directors Talk | September 17, 2021

Midatech Pharma to release its interim results on Friday 17 September 2021

Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced that it will release its interim results for the six months ended 30 June 2021 at 7.00 am BST on Friday 17 September 2021. The Company will be hosting a webinar at 5.30pm BST / []

Directors Talk | September 6, 2021

Midatech Pharma PLC Announces Notice of Interim Results

ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 6, 2021 / Midatech Pharma PLC (AIM:MTPH)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of

FinanzNachrichten | September 6, 2021

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Inclining Growth by 2021-2028| WEX Pharmaceuticals, Asahi Kasei, MediciNova, Achelios Therapeutics, Esteve, ChromaDex, Apollo Endosurgery, Hoffmann-La Roche, Midatech/DARA, Lee''s Pharmaceutical Limi

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes

OpenPR | August 31, 2021

Read More 'MTP' Stories Here

MTP Price Returns

1-mo -18.13%
3-mo -22.65%
6-mo -27.46%
1-year -27.84%
3-year -88.80%
5-year -99.00%
YTD -25.13%
2020 -45.74%
2019 -55.53%
2018 -81.55%
2017 -69.57%
2016 -43.09%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0359 seconds.